For brain-metastasis trials, eligibility can hinge on neurological stability and prior steroid use. T-MAXIMUM says the FDA has cleared it to start a Phase 2 study of MT027 in patients with brain metastases from lung and breast cancer.
The company has also reported an earlier FDA clearance for a Phase 2 study in recurrent glioblastoma. Neither clearance is a marketing approval. FDA and ClinicalTrials.gov results available for this update did not independently confirm the reported brain-metastasis clearance, so the study’s timing and enrollment status could not be verified.
That distinction matters in a disease setting where systemic cancer treatments may not adequately address brain lesions. The blood-brain barrier and tumor heterogeneity can complicate treatment, while doctors also need to preserve neurological function. International estimates cited by the company suggest about 20% of cancer patients develop brain metastases during their disease. Among people with advanced solid tumors, estimates rise to 20%–40%.
A separate stereotactic-radiotherapy report covered 29 patients with 130 brain metastases treated between December 2018 and March 2023. Twelve-month intracranial progression-free survival was 43.6%; radionecrosis occurred in 13 lesions across nine patients. These results concern radiotherapy, not MT027.
Published eligibility criteria for another cancer trial required patients with brain metastases to be neurologically stable and, depending on their metastasis status, off glucocorticoids for 7–28 days. Such criteria are trial-specific and cannot be assumed to apply to MT027.
Early signals remain preliminary
T-MAXIMUM describes MT027 as a B7-H3-targeted allogeneic CAR-T therapy, made through a fully non-viral gene-editing process and delivered locally inside the skull. The company says it established and locked the manufacturing process before Phase 2 development. It also claims potential gains in safety, consistency and cost control. Materials reviewed did not independently confirm the manufacturing details or those claimed advantages. FDA clearance alone does not establish them.
At the IASLC 2026 World Conference on Lung Cancer, the company reported early MT027 data from five heavily pretreated patients with lung cancer brain metastases. Three patients could be evaluated, and two had partial responses. No Grade 3 or higher adverse events or graft-versus-host disease were reported. Those results come from a small early dataset and cannot show how MT027 will perform in a larger study.
A separate stereotactic-radiotherapy analysis reported outcomes in patients treated for multiple brain metastases. Its findings concern radiotherapy, not MT027.
The company has also reported that an investigator-initiated trial of MT026, a program on the same platform, was published in Nature Communications in 2026. Among five patients with recurrent high-grade glioma, the report described one complete response and three partial responses, for an objective response rate of 80%. No treatment-related Grade 3 or higher adverse events were reported. These findings concern MT026, not MT027. The materials reviewed did not independently confirm the stated publication or results, and the available Springer glial-stem-cell index does not confirm the reported study. Early CAR-T results in other cancers, including this ovarian cancer report, do not verify MT027’s performance in a larger trial.
Two indications enter Phase 2 development
The company estimates that brain metastases account for 200,000 to 300,000 new diagnoses each year in the United States. Lung and breast cancers are among the leading primary sources. T-MAXIMUM says the reported study will test whether MT027 can offer a local treatment approach for patients whose disease progresses in the brain after prior treatment.
According to the company, MT027 has Orphan Drug Designation for high-grade glioma and Fast Track Designation for recurrent or progressive glioblastoma. Those designations and the reported Phase 2 clearances are regulatory milestones, not proof that the therapy works.
The evidence reported so far comes from small cohorts and company-reported results. The trials will need to establish safety and clinical benefit in the intended patients.
